Pharma
CONEXEN FEBRUARY 2023 - CAMBRIDGE
What is CONEXEN (Connect, Engage, Exchange)?
New Year, new you, new offer from The Jockey Club
For every NEW conference booked and confirmed to take place from 5th January to 31st March 2023, you can take your pick from a variety of options to add to your Day Delegate package from Danish pastries to fresh fruit platters and add them to your event, completely free of charge! We c...
CRUK Cambridge Institute ~ Meet the i.prep and Veon Scientific
Meet the i.prep ~ the simple way to automate manual pipetting tasks, or complement your high throughput screening with efficient hit picking. ...
Measuring the dew point for nitrogen and oxygen in gas generators
For many companies, there are considerable advantages to using industrial gas generators, rather than traditional bottled or tanker supply to on-site silos. However, the benefits only accrue if the gas generator is operating at optimum levels of efficiency and reliability. This is where...
University of Exeter enters virtual screening collaboration with Cresset Discovery to accelerate discovery of novel antimicrobial drugs
Cresset Discovery, provider of molecular modeling expertise for drug discovery, is collaborating with the University of Exeter to find new antimicrobial drugs. Cresset Discovery will deploy its expertise in virtual screening to identify promising new candidates, building on research led...
The year in review: Updates and trends
In 2022, everyone witnessed intense activity in matters related to supply chain issues, the energy transition, oil & gas, post-M&A disputes, licensing issues, breaches of distribution contracts and increasingly arbitrations deriving from geopolitical issues in Europe and Asia an...
Assessing the impact of rarity on French HTA and pricing decisions
With changes to the pricing and access processes such as the new Accord Cadre and the soon-to-be implemented ATU reform likely to impact pricing and access of orphan products in France, Cécile Matthews, Bhavesh Patel, and Owen Male look at how French payers have valued rarity in the pas...
How eligible patient numbers affect price of rare disease drugs in France
Having recently assessed the relationship between drug price and prevalence of non-oncology rare diseases, CRA’s Cécile Matthews, Bhavesh Patel, and Owen Male explore in greater depth the situation for these orphan drugs in France in this final article of a three-part series published i...
France’s ATU reform: Early access remains possible, but not all diseases are equal
When France’s ATU reform was implemented, some viewed it as restrictive. In this article published in European Pharmaceutical Review (EPR), Cécile Matthews and Charlotte Capdevila explore the reform’s impact on early access to oncology drugs and products for rare diseases. ...
TTP introduces Cellular Origins, a TTP Company focussed on delivering scalable manufacture of cell and gene therapies
TTP plc (TTP), a leading independent technology and product development company, has today announced the launch of Cellular Origins, a TTP Company. Cellular Origins is a TTP spin-out, created to enable scalable, cost-effective and efficient manufacture of cell and gene therapies. Cellul...